Recently, President Trump signed a “most-favored nation” executive order on drug prices with a claim that it would force pharmaceutical companies to lower U.S. prescription costs to match those abroad. As a result, the White House announced a deal with Pfizer to lower drug prices and a new direct-to-consumer website dubbed “TrumpRx.”
But none of these actions will lead to substantial savings for the government or patients. This is all just political theater — in fact, pharmaceutical stocks rose after the order was signed and significantly rose again after the announcement with Pfizer.
STAT Pharma: The science and business of new drug development
Leave a Reply